Jane Street Group LLC Lowers Position in 23andMe Holding Co. (NASDAQ:ME)

Jane Street Group LLC decreased its position in shares of 23andMe Holding Co. (NASDAQ:ME) by 68.3% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 726,017 shares of the company’s stock after selling 1,561,678 shares during the period. Jane Street Group LLC owned approximately 2.96% of 23andMe worth $252,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in ME. Vanguard Personalized Indexing Management LLC increased its holdings in shares of 23andMe by 410.4% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 88,555 shares of the company’s stock worth $35,000 after buying an additional 71,204 shares during the period. Point72 DIFC Ltd purchased a new position in shares of 23andMe in the second quarter worth about $43,000. AQR Capital Management LLC increased its holdings in shares of 23andMe by 145.8% in the second quarter. AQR Capital Management LLC now owns 444,222 shares of the company’s stock worth $174,000 after buying an additional 263,468 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of 23andMe in the second quarter worth about $203,000. Finally, FMR LLC increased its holdings in shares of 23andMe by 24.0% in the third quarter. FMR LLC now owns 993,848 shares of the company’s stock worth $345,000 after buying an additional 192,099 shares during the period. Hedge funds and other institutional investors own 36.10% of the company’s stock.

23andMe Price Performance

NASDAQ ME opened at $3.84 on Friday. The business’s 50-day moving average is $3.62 and its 200 day moving average is $5.81. The stock has a market capitalization of $100.29 million, a PE ratio of -0.15 and a beta of 1.14. 23andMe Holding Co. has a 1 year low of $2.65 and a 1 year high of $16.52.

23andMe (NASDAQ:ME) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($2.32) earnings per share for the quarter. The firm had revenue of $44.07 million for the quarter, compared to the consensus estimate of $50.30 million. 23andMe had a negative net margin of 318.39% and a negative return on equity of 129.98%.

23andMe Profile

23andMe Holding Co operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications.